Compare BioNano Genomics Inc (BNGO) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Expedia Group Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Expedia Group Inc trades at $270.59 (market cap $31.96B). The key difference: Expedia Group Inc is far larger — about 2421.2× BioNano Genomics Inc's market cap, and Expedia Group Inc pays a 0.66% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | EXPE | |
|---|---|---|
Market Cap | $13.20M | $31.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $301.31 |
52-Week Low | $1.09 | $178.06 |
Enterprise Value | $15.81M | $30.87B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Expedia Group (EXPE) trades at $265.63, down 1.92% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $287.90 implying 8.4% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.96 surpassing expectations of $1.41. Revenue grew to $14.73B in 2025, and net income reached $1.29B, supported by a high gross profit margin of 90.27%. Recent developments include a strategic partnership with Allegiant Travel and upcoming Q2 2026 earnings on August 5, 2026.
The outlook for EXPE is positive, driven by earnings momentum, strategic partnerships, and analyst optimism, but risks include travel sector volatility and high debt levels. The stock presents a growth opportunity with reasonable valuation multiples (P/E 23.47, EV/EBITDA 9.99), though investors should monitor competitive pressures and macroeconomic impacts on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
